scholarly journals Extracellular Matrix–Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer

2020 ◽  
Vol Volume 13 ◽  
pp. 12521-12538
Author(s):  
Liangliang Qing ◽  
Peng Gu ◽  
Mingsheng Liu ◽  
Jihong Shen ◽  
Xiaodong Liu ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Bladder Cancer ◽  
Prognostic Biomarker

scholarly journals EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yue Yang ◽  
Hanchao Zhang ◽  
Zhengdao Liu ◽  
Faliang Zhao ◽  
Guobiao Liang
Keyword(s):  
Bladder Cancer ◽  
T Cells ◽  
Prognostic Biomarker ◽  
Transmembrane Protein ◽  
Tumor Stage ◽  
Receptor Interaction ◽  
Advanced Tumor Stage ◽  
Normal Bladder ◽  
Advanced Tumor ◽  
Significant Difference

AbstractBackgroundBladder cancer (BLCA) is a malignant urothelial carcinoma and has a high mortality rate. EPDR1 (ependymin related 1) is a type II transmembrane protein and related to calcium-dependent cell adhesion.MethodsWe explored the potential oncogenic roles of EPDR1 in BLCA basing on the multiple public datasets.ResultsWe found that EPDR1 expression had a significant difference in BLCA and adjacent normal bladder tissues, and the level of EPDR1was up-regulated with advanced tumor stage and metastasis in BLCA. Meanwhile, the high expression group of EPDR1 had a shorter OS compared to the low or medium expression-group. Furthermore, EPDR1 expression was associated with tumor-infiltrating immune cells (TIICs), including NK cells, CD8 + T cells, CD4 + T cells, Macrophages cells, and so on. Moreover, EPDR1 also involved in several signaling pathways as well as PI3K/AKT pathway, Cytokine receptor interaction, and apoptosis.ConclusionEPDR1 can be used as a novel prognostic biomarker as well as an effective target for diagnosis and treatment in BLCA.

scholarly journals Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance

Neoplasma ◽  
2019 ◽  
Vol 66 (02) ◽  
pp. 197-202 ◽  
Author(s):  
B. J. Chi ◽  
D. M. Zhao ◽  
L. Liu ◽  
X. Z. Yin ◽  
F. F. Wang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cisplatin Resistance ◽  
Prognostic Biomarker

scholarly journals Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer

2016 ◽  
Vol 27 (2) ◽  
pp. 294-299 ◽  
Author(s):  
N. Joseph ◽  
S.J. Dovedi ◽  
C. Thompson ◽  
J. Lyons ◽  
J. Kennedy ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Biomarker ◽  
Advanced Bladder Cancer ◽  
Pre Treatment ◽  
Muscle Invasive

scholarly journals Suppression and Activation of the Malignant Phenotype by Extracellular Matrix in Xenograft Models of Bladder Cancer: A Model for Tumor Cell “Dormancy”

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e64181 ◽  
Author(s):  
Robert E. Hurst ◽  
Paul J. Hauser ◽  
Kimberly D. Kyker ◽  
Jonathan E. Heinlen ◽  
Jason P. Hodde ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Bladder Cancer ◽  
Tumor Cell ◽  
Malignant Phenotype ◽  
Xenograft Models ◽  
Cell Dormancy

scholarly journals FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Guanwen Zhou ◽  
Keqiang Yan ◽  
Jikai Liu ◽  
Lijian Gao ◽  
Xianzhou Jiang ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Bladder Cancer ◽  
Cancer Cell ◽  
Cancer Progression ◽  
Prognostic Biomarker ◽  
Critical Role ◽  
Bladder Cancer Cell ◽  
Dependent Manner ◽  
Cancer Cell Proliferation ◽  
Aberrant Expression

AbstractThe aberrant expression of fat mass and obesity-associated protein (FTO) has been confirmed to be associated with a variety of cancers and participates in the regulation of multiple biological behaviours. FTO plays an oncogenic role in bladder cancer, but few studies have focused on how FTO promotes bladder cancer progression by regulating miRNA synthesis. Here, we confirmed that FTO expression was significantly increased in bladder cancer and was associated with a poor prognosis. FTO overexpression promoted bladder cancer cell proliferation, whereas FTO knockdown inhibited bladder cancer cell proliferation. We also demonstrated that FTO promoted bladder cancer cell proliferation via the FTO/miR-576/CDK6 pathways. Taken together, our work revealed that FTO plays a critical role in bladder cancer and could be a potential diagnostic or prognostic biomarker for this disease.

scholarly journals Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Xingyu Chen ◽  
Haotian Chen ◽  
Dong He ◽  
Yaxin Cheng ◽  
Yuxing Zhu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Microenvironment ◽  
Cancer Progression ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Immune Cell ◽  
Cox Regression ◽  
Prognostic Biomarker ◽  
Checkpoint Inhibitor ◽  
Clinical Prognosis

The tumor microenvironment (TME) plays a crucial role in cancer progression and recent evidence has clarified its clinical significance in predicting outcomes and efficacy. However, there are no studies on the systematic analysis of TME characteristics in bladder cancer. In this study, we comprehensively evaluated the TME invasion pattern of bladder cancer in 1,889 patients, defined three different TME phenotypes, and found that different subtypes were associated with the clinical prognosis and pathological characteristics of bladder cancer. We further explored the signaling pathways, cancer-immunity cycle, copy number, and somatic mutation differences among the different subtypes and used the principal component analysis algorithm to calculate the immune cell (IC) score, a tool for comprehensive evaluation of TME. Univariate and multivariate Cox regression analyses showed that ICscore is a reliable and independent prognostic biomarker. In addition, the use of anti-programmed death-ligand (PD-L1) treatment cohort, receiver operating characteristic (ROC) curve, Tumor Immune Dysfunction and Exclusion (TIDE), Subnetwork Mappings in Alignment of Pathways (SubMAP), and other algorithms confirmed that ICscore is a reliable prognostic biomarker for immune checkpoint inhibitor response. Patients with higher ICscore showed a significant therapeutic advantage in immunotherapy. In conclusion, this study improves our understanding of the characteristics of TME infiltration in bladder cancer and provides guidance for more effective personalized immunotherapy strategies.

scholarly journals Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer

2018 ◽  
Author(s):  
Hiroshi Fukushima ◽  
Kosuke Takemura ◽  
Hiroaki Suzuki ◽  
Fumitaka Koga
Keyword(s):  
Skeletal Muscle ◽  
Bladder Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Prognostic Biomarker ◽  
Inflammatory Diseases ◽  
Poor Nutritional Status ◽  
Lack Of Exercise ◽  
Worse Prognosis

Sarcopenia, the degenerative and systemic loss of skeletal muscle mass, indicates patient frailty and impaired physical function. Sarcopenia can be caused by multiple factors, including advanced age, lack of exercise, poor nutritional status, inflammatory diseases, endocrine diseases, and malignancies. Recently, growing evidence has indicated the importance of sarcopenia in the management of patients with various cancers. Sarcopenia is associated with not only higher rates of treatment-related complications but also worse prognosis in cancer-bearing patients. In this article, we conducted a systematic literature review regarding the significance of sarcopenia as a prognostic biomarker of bladder cancer. We also reviewed recent studies focusing on the prognostic role of changes in skeletal muscle mass during the course of treatment in bladder cancer patients.

Sign in / Sign up

Export Citation Format

Share Document